|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/ Epo human leukemia cell line.
|
24761846 |
2014 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data support the testing of type II JAK2 inhibition in patients with JAK2-dependent leukemias and other disorders.
|
26175414 |
2015 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Supporting the notion that LT signalling plays a role in T-ALL, inactivation of Ltbr results in a significant delay in TEL-JAK2-induced leukaemia onset.
|
26456771 |
2015 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Having both a tyrosine kinase-activating rearrangement and genomic lesions affecting lymphoid transcription factors suggested that the leukemia was of the Philadelphia chromosome (Ph)/BCR-ABL1-like ALL subtype and that JAK2 inhibitors might be able to overcome this aggressive ALL with SPAG9-JAK2.
|
25951811 |
2015 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SHP1 negatively regulates the Janus kinase 2/signal transducer and activator of transcription (JAK2/STAT) signaling pathway, which is constitutively activated in myeloproliferative neoplasms (MPNs) and leukemia.
|
25824741 |
2015 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this report, we proposed that miRNA-101 targets Jak2 mRNA and regulates its expression and induces K562 leukemia cell apoptosis.
|
27517565 |
2016 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In particular, gain-of-function mutations in the <i>JAK</i> genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.
|
29379470 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Survival was longer in JAK2 V617F-unmutated leukaemia (343 days vs. 95 days, P = 0·003).
|
28542718 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative leukemia virus gene is mutated.
|
27686378 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis.
|
28331226 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 and SRSF2 mutation were not associated with increased leukemia transformation.
|
29970342 |
2018 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While expression of mutant Jak2 was necessary for leukemia induction, neither its continued expression nor enzymatic activity was required to maintain leukemia survival and rapid proliferation.
|
29907650 |
2018 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
|
29940115 |
2018 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 clinical mutations cause myeloproliferative neoplasms and leukemia, and the mutations strongly concentrate in the regulatory pseudokinase domain Janus kinase homology (JH) 2.
|
30092288 |
2019 |